Cardiol Therapeutics (TSX:CRDL) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cardiol Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was C$-6.93 Mil. Cardiol Therapeutics's Revenue for the three months ended in Mar. 2024 was C$0.00 Mil. Therefore, Cardiol Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Cardiol Therapeutics's current FCF Yield % is -8.93%.

The historical rank and industry rank for Cardiol Therapeutics's FCF Margin % or its related term are showing as below:

During the past 7 years, the highest FCF Margin % of Cardiol Therapeutics was -29813.92%. The lowest was -29813.92%. And the median was -29813.92%.

TSX:CRDL's FCF Margin % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.16
* Ranked among companies with meaningful FCF Margin % only.

Cardiol Therapeutics FCF Margin % Historical Data

The historical data trend for Cardiol Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics FCF Margin % Chart

Cardiol Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-29,813.92

Cardiol Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cardiol Therapeutics's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiol Therapeutics's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cardiol Therapeutics's FCF Margin % falls into.

Cardiol Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cardiol Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-25.244	/	0
	=	%

Cardiol Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-6.926	/	0
	=	%

Cardiol Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiol Therapeutics (TSX:CRDL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CRDL:USA CT9:Germany

Address

2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5

Website

https://www.cardiolrx.com

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Executives

Guillermo Torre

Senior Officer